There are several factors that may affect future arrangements which are subject to legislation or the Department’s relationship with other bodies. They include, for example, the role of NICE and related issues such as thresholds, where the ABPI has never had any right of direct intervention or negotiation.
However, both DH and the ABPI recognise that developments in these areas will have an impact on negotiations, particularly regarding the evolution of value-based pricing. We have therefore agreed with the Department to hold separate meetings on these matters. The content of these meetings will be reported back to meetings of the negotiating teams for their information to ensure an holistic basis of common understanding for a new scheme. Any such parallel meetings will be attended by a member of the ABPI Negotiating Team to ensure seamless integration.
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811 Email: email@example.com
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.